Ireland has taken an important step for approximately 200 patients living with Friedreich's ataxia. The Health Service Executive's senior management team approved reimbursement of Skyclarys, the first licensed treatment for the rare progressive neurological condition, on 25 August 2026, following a substantially improved commercial offer from Biogen, the drug's manufacturer. For patients who have waited years for access to the only medicine capable of slowing their disease's progression, the decision represents a genuinely meaningful clinical milestone. For Ireland's pharmaceutical and life sciences community, it also opens a constructive and necessary conversation about how the country's rare disease reimbursement architecture can be strengthened so that future patients reach treatment faster, with less personal cost, and through a process that reflects Ireland's ambition to be a world-class healthcare system as well as a world-class pharmaceutical manufacturing nation.

The clinical significance of Skyclarys is not in dispute. Omaveloxolone is the first licensed therapy for Friedreich's ataxia, a condition that causes progressive nervous system damage, loss of muscle coordination, and shortened life expectancy. It does not cure the condition, but patients and clinicians report that it slows disease progression in ways that have real functional consequences for daily living. The HSE's recognition of the substantial unmet need and the absence of alternatives reflects the clinical reality that for ultra-rare diseases affecting small patient populations, conventional cost-effectiveness frameworks built around high-volume treatment populations are poorly calibrated. The National Centre for Pharmacoeconomics' assessment, which cited a price of approximately €280,000 per patient per year and clinical data uncertainties, is a technically defensible output of a framework designed for a different category of medicine. The Skyclarys decision demonstrates that Ireland's system is capable of finding solutions when that framework reaches its limits, and that is a positive foundation to build from.

The international context is equally encouraging. Ireland's National Rare Disease Plan 2019 to 2027 commits to improving access to orphan medicines through enhanced engagement with the European Reference Networks and the EMA's accelerated assessment pathways. The EU's Pharmaceutical Legislation Reform, advancing during Ireland's EU Presidency term, includes specific provisions to strengthen access to rare disease treatments across member states, including regulatory incentives for orphan drug development and improved coordination of health technology assessment through the EU HTA Regulation, which came into force for oncology and advanced therapy medicinal products in January 2025 and will extend to orphan medicines by 2028. Ireland's Presidency provides a direct opportunity to champion faster, more consistent rare disease reimbursement pathways across EU member states, using the Skyclarys case as evidence that commercially negotiated access solutions can succeed where standard pharmacoeconomic assessments reach their limits.

Three actions would allow Ireland to build positively on the Skyclarys decision and strengthen its rare disease medicine access framework. First, the HSE and the Department of Health should establish a dedicated managed access pathway for ultra-rare disease treatments with no therapeutic alternatives, modelled on the UK's NHS Innovative Medicines Fund and Germany's AMNOG early benefit assessment framework, enabling conditional reimbursement with real-world evidence collection rather than requiring full cost-effectiveness approval before any patient access begins. Second, pharmaceutical companies developing rare disease treatments should engage with the HPRA's scientific advice service at the earliest stage of Irish market planning, using pre-submission dialogue to align clinical evidence packages with the specific data requirements of Ireland's pharmacoeconomic assessment process and reducing the uncertainty that delayed Skyclarys approval. Third, Ireland's Department of Health should use its EU Presidency platform to advance a shared rare disease reimbursement coordination mechanism across member states, building on the Joint Clinical Assessments framework to ensure that small patient population medicines are evaluated against appropriate comparators and access timelines that reflect the unmet clinical need rather than the commercial norms of high-volume therapeutic categories.

The Skyclarys decision is a good outcome for Irish patients with Friedreich's ataxia, and it reflects the genuine commitment within Ireland's health system to find solutions for people with rare conditions. The opportunity now is to ensure that future patients reach treatment through a pathway designed for their circumstances from the outset, rather than through a campaign that should never have been necessary.